An iRGD Peptide Fused Superantigen Mutant Induced Tumor-Targeting and T Lymphocyte Infiltrating in Cancer Immunotherapy

2020 ◽  
Author(s):  
Yubo Song ◽  
Mingkai Xu ◽  
Yongqiang Li ◽  
Yansheng Li ◽  
Wu Gu ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
T Lymphocyte ◽  
Tumor Targeting

An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy

2020 ◽  
Vol 586 ◽  
pp. 119498 ◽  
Author(s):  
Yubo Song ◽  
Mingkai Xu ◽  
Yongqiang Li ◽  
Yansheng Li ◽  
Wu Gu ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
T Lymphocyte ◽  
Tumor Targeting

scholarly journals HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes from Human Hepsin as Novel Targets for Prostate Cancer Immunotherapy

2013 ◽  
Vol 78 (3) ◽  
pp. 248-257 ◽  
Author(s):  
J. Guo ◽  
G. Li ◽  
J. Tang ◽  
X.-B. Cao ◽  
Q.-Y. Zhou ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Immunotherapy ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Novel Targets

scholarly journals Chitosan thermogels for local T lymphocyte delivery for cancer immunotherapy

2015 ◽  
Vol 3 (S2) ◽  
Author(s):  
Anne Monette ◽  
Caroline Ceccaldi ◽  
Sophie Lerouge ◽  
Réjean Lapointe
Keyword(s):  
Cancer Immunotherapy ◽  
T Lymphocyte

Photosensitizer-induced self-assembly of antigens as nanovaccines for cancer immunotherapy

2018 ◽  
Vol 6 (3) ◽  
pp. 473-477 ◽  
Author(s):  
F. Q. Cao ◽  
M. M. Yan ◽  
Y. J. Liu ◽  
L. X. Liu ◽  
L. Lu ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Laser Irradiation ◽  
T Lymphocyte ◽  
Self Assembly ◽  
Near Infrared ◽  
Cytotoxic T Lymphocyte ◽  
Lymphocyte Response ◽  
Cross Presentation ◽  
Cytotoxic T Lymphocyte Response ◽  
Nir Laser

Under near-infrared (NIR) laser irradiation, ICG–antigen conjugate-based nanovaccines enhanced the cross-presentation of antigens and induced cytotoxic T lymphocyte response.

scholarly journals Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy

2021 ◽  
Vol 12 ◽  
Author(s):  
Muhammad Khan ◽  
Sumbal Arooj ◽  
Hua Wang
Keyword(s):  
Cancer Immunotherapy ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Chronic Infections ◽  
Tumor Immune Evasion ◽  
Checkpoint Proteins ◽  
Cell Responses ◽  
Anti Cancer ◽  
Immune Checkpoint Proteins ◽  
Proteolytic Shedding

Co-inhibitory B7-CD28 family member proteins negatively regulate T cell responses and are extensively involved in tumor immune evasion. Blockade of classical CTLA-4 (cytotoxic T lymphocyte-associated antigen-4) and PD-1 (programmed cell death protein-1) checkpoint pathways have become the cornerstone of anti-cancer immunotherapy. New inhibitory checkpoint proteins such as B7-H3, B7-H4, and BTLA (B and T lymphocyte attenuator) are being discovered and investigated for their potential in anti-cancer immunotherapy. In addition, soluble forms of these molecules also exist in sera of healthy individuals and elevated levels are found in chronic infections, autoimmune diseases, and cancers. Soluble forms are generated by proteolytic shedding or alternative splicing. Elevated circulating levels of these inhibitory soluble checkpoint molecules in cancer have been correlated with advance stage, metastatic status, and prognosis which underscore their broader involvement in immune regulation. In addition to their potential as biomarker, understanding their mechanism of production, biological activity, and pathological interactions may also pave the way for their clinical use as a therapeutic target. Here we review these aspects of soluble checkpoint molecules and elucidate on their potential for anti-cancer immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document